Overview

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Status:
Active, not recruiting
Trial end date:
2022-09-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of KP104 and Part 2, multiple ascending dose (MAD).
Phase:
Phase 1
Details
Lead Sponsor:
Kira Pharmacenticals (US), LLC.